Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

499 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The interaction of de novo and pre-existing aortic regurgitation after TAVI: insights from a new quantitative aortographic technique.
Tateishi H, Abdelghani M, Cavalcante R, Miyazaki Y, Campos CM, Collet C, Slots TLB, Leite RS, Mangione JA, Abizaid A, Soliman OII, Spitzer E, Onuma Y, Serruys PW, Lemos PA, de Brito FS Jr. Tateishi H, et al. Among authors: abizaid a. EuroIntervention. 2017 May 15;13(1):60-68. doi: 10.4244/EIJ-D-16-00647. EuroIntervention. 2017. PMID: 27993754 Free article.
Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial.
Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A, Guagliumi G, Wijns W, Lindeboom WK, Ligthart J, de Feyter PJ, Morice MC; RAVEL Study Group. Serruys PW, et al. Among authors: abizaid a. Circulation. 2002 Aug 13;106(7):798-803. doi: 10.1161/01.cir.0000025585.63486.59. Circulation. 2002. PMID: 12176950 Free article. Clinical Trial.
The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES).
Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H, Smits P, McClean D, Verheye S, Belardi J, Condado J, Pieper M, Gambone L, Bressers M, Symons J, Sousa E, Litvack F. Serruys PW, et al. Among authors: abizaid a. J Am Coll Cardiol. 2005 Jul 19;46(2):253-60. doi: 10.1016/j.jacc.2005.03.069. J Am Coll Cardiol. 2005. PMID: 16022951 Free article. Clinical Trial.
Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients.
Aoki J, Abizaid AC, Serruys PW, Ong AT, Boersma E, Sousa JE, Bruining N. Aoki J, et al. J Am Coll Cardiol. 2005 Nov 1;46(9):1670-6. doi: 10.1016/j.jacc.2005.06.076. Epub 2005 Oct 10. J Am Coll Cardiol. 2005. PMID: 16256867 Free article.
One-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer - Insight in the Paclitaxel In-Stent Controlled Elution Study (PISCES).
Aoki J, Ong AT, Abizaid A, den Heijer P, Bonnier H, McClean DR, Verheye S, Belardi J, Condado JA, Pieper M, Sousa JE, Bressers M, Symons J, Litvack F, Sianos G, Serruys PW. Aoki J, et al. Among authors: abizaid a. EuroIntervention. 2005 Aug;1(2):165-72. EuroIntervention. 2005. PMID: 19758898
A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study.
Serruys PW, Garg S, Abizaid A, Ormiston J, Windecker S, Verheye S, Dubois C, Stewart J, Hauptmann KE, Schofer J, Stangl K, Witzenbichler B, Wiemer M, Barbato E, de Vries T, den Drijver AM, Otake H, Meredith L, Toyloy S, Fitzgerald P. Serruys PW, et al. Among authors: abizaid a. EuroIntervention. 2010 Jun;6(2):195-205. EuroIntervention. 2010. PMID: 20562069 Clinical Trial.
499 results